BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH
“Together, BIOCRATES and Metanomics Health provide the broadest technology and metabolomics product portfolio in the industry. These will enable us to provide deep metabolic phenotyping through targeted metabolomics profiling services, customized assays, targeted screening kits, and comprehensive data interpretation. Moreover, the merger will enable us to develop kits for both Diagnostics and Companion Diagnostics”, said BIOCRATES’ CEO Dr. Wulf Fischer-Knuppertz. “We are looking forward to further developing and expanding our offerings in the life science market. The completed financing round along with the merger allows us to increase our growth through accelerated kit development and regional sales expansion.”
Dr. Tim Bölke, Metanomics Health’s Managing Director, who will continue to lead operations in Berlin and join the management team of BIOCRATES as Chief Medical Officer commented: “Metabolomics has the potential to bring a new dimension to diagnosis and patient stratification in precision medicine as well as to improve the drug discovery and development process. We are looking forward to extending and broadening our services and offerings to improve prognosis and diagnosis in areas of high unmet medical need, ultimately leading to earlier and better treatments.”
BASF Plant Science GmbH, MIG Fonds and GA Asset Fund GmbH & Co. KG (GAF) participated in the financing round.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.